AIRS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.64
- P/S (TTM)
- 1.02
- EV/EBITDA
- 267.32
Profitability & growth
- ROE (TTM)
- -12.0%
- Operating margin
- -0.1%
- Revenue growth YoY
- -2.5%
- Dividend yield
- —
- Beta
- 2.29
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Airsculpt Technologies Inc
Company profileAirsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its…
Classification
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2023 WEST PLATT STREET, TAMPA, FL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer